An overview about the risks of surgical septal myectomy and alcohol ablation as treatments for obstructive hypertrophic cardiomyopathy and how mavacamten can provide an alternative was given by Prof. Milind Desai (Cleveland Clinic, Cleveland, OH).
The presentation entitled ‘VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy’ was presented at the American College of Cardiology Annual Meeting 2022, April 02-04, 2022
Questions:
- Could you give us a brief overview of surgical septal myectomy and alcohol ablation as treatments for obstructive hypertrophic cardiomyopathy, and the risks posed by these treatments? (00:26)
- How can mavacamten provide an alternative to these invasive treatments? (03:30)
Disclosures: Milind Desai is a consultant for Bristol Myers Squibb and Medtronic.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
